tiprankstipranks
Advertisement
Advertisement

RCKT Stock Latest News

Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
RatingsBalanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
4d ago
RCKT
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
PremiumRatings
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
7d ago
RCKT
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
PremiumThe Fly
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
7d ago
RCKT
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
PremiumCompany Announcements
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
17d ago
8K
RCKT
Rocket Pharmaceuticals announces $180M sale of priority review voucher
PremiumThe Fly
Rocket Pharmaceuticals announces $180M sale of priority review voucher
17d ago
RCKT
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
PremiumCompany AnnouncementsRocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
29d ago
RCKT
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
Premium
The Fly
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
2M ago
RCKT
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
Premium
Ratings
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
2M ago
RCKT
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
2M ago
RCKT
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
PremiumThe Fly
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
2M ago
RCKT
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
PremiumThe Fly
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
2M ago
RCKT
Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
PremiumRatings
Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
2M ago
RCKT
Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
PremiumRatingsRocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
2M ago
RCKT
Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
Premium
Ratings
Rocket Pharmaceuticals: First Approval and Extended Cash Runway Offset by Long Path to Meaningful Kresladi Revenues, Warranting a Hold Rating
2M ago
RCKT
Video: Unity rises after better-than-expected pre-announcement
Premium
The Fly
Video: Unity rises after better-than-expected pre-announcement
2M ago
U
AGX
Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy
PremiumCompany Announcements
Rocket Pharmaceuticals wins FDA nod for KRESLADI gene therapy
2M ago
8K
RCKT
Rocket Pharmaceuticals announces FDA approval of Kresladi
PremiumThe Fly
Rocket Pharmaceuticals announces FDA approval of Kresladi
2M ago
RCKT
Rocket Pharmaceuticals: FDA Approval of Kresladi Marks Strategic Inflection Point Supporting Buy Rating
PremiumRatings
Rocket Pharmaceuticals: FDA Approval of Kresladi Marks Strategic Inflection Point Supporting Buy Rating
2M ago
RCKT
FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I
PremiumThe Fly
FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I
2M ago
RCKT
Rocket Pharma Advances BAG3 Heart Disease Study, Bolstering Long-Term Gene Therapy Story
PremiumCompany AnnouncementsRocket Pharma Advances BAG3 Heart Disease Study, Bolstering Long-Term Gene Therapy Story
2M ago
RCKT
Rocket Pharmaceuticals Launches New $100M At-The-Market Program
Premium
Company Announcements
Rocket Pharmaceuticals Launches New $100M At-The-Market Program
2M ago
8K
RCKT
Rocket Pharmaceuticals offers to sell up to $100M in common stock
Premium
The Fly
Rocket Pharmaceuticals offers to sell up to $100M in common stock
2M ago
RCKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >